Clinical Trials
ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Studies listed here represent active and ongoing clinical trials in the United States and Canada. Please click on the links for more information on each study including eligibility requirements and study locations. Studies listed are intended to provide a reference for trials related to rheumatologic skin disease, but the list is not comprehensive nor are the studies included specifically endorsed by RDS.
Lupus
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy Sat, Sep 21, 2024
- A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier Wed, Apr 17, 2024
- Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique Mon, Apr 15, 2024
- Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases Fri, Apr 12, 2024
- A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus Thu, Apr 11, 2024
- Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus Wed, Apr 10, 2024
- Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study Fri, Apr 05, 2024
Dermatomyositis
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy Sat, Sep 21, 2024
- A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Evaluating Tools to Communicate Scleroderma Research Results to Patients Thu, Apr 18, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy Sat, Sep 21, 2024
- A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Evaluating Tools to Communicate Scleroderma Research Results to Patients Thu, Apr 18, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy Sat, Sep 21, 2024
- A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Evaluating Tools to Communicate Scleroderma Research Results to Patients Thu, Apr 18, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
Systemic sclerosis
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy Sat, Sep 21, 2024
- A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Evaluating Tools to Communicate Scleroderma Research Results to Patients Thu, Apr 18, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
Morphea
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy Sat, Sep 21, 2024
- A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Evaluating Tools to Communicate Scleroderma Research Results to Patients Thu, Apr 18, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
Vasculitis
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy Sat, Sep 21, 2024
- A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease Thu, Apr 18, 2024
- Evaluating Tools to Communicate Scleroderma Research Results to Patients Thu, Apr 18, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Apr 17, 2024
Clinical Registries
Lupus:
Cutaneous Lupus Registry at University of Pennsylvania Medical Center in Philadelphia, PA
Dermatologists at Penn established a registry for cutaneous lupus patients in 2006 to gather the large number of patients necessary for studies to better understand the development of the disease and improve our methods of diagnosis, prognosis, and treatment. The database includes a blood and tissue bank CLE Tissue Bank, which was started at Penn in 2009 as a foundation for genetic, biomarker and pathophysiologic studies.
The principal investigator for the study is Victoria Werth, MD, Professor of Dermatology at the University of Pennsylvania, an expert in the treatment of cutaneous lupus. For more information, please go to
http://www.uphs.upenn.edu/dermatology/research-clinical-trials/clinical-trials.html
Cutaneous Lupus Registry at University of Texas Southwestern Medical Center in Dallas, TX
Dermatologists at UT Southwestern have established a registry for cutaneous lupus patients and their relatives in order to gather the large number of patients necessary for studies to better understand the development of the disease and improve our methods of diagnosis, prognosis, and treatment. This registry will provide a resource for investigators to make discoveries in regards to both the clinical and molecular aspects of the disease. The principal investigator for the study is Benjamin Chong, MD, assistant professor of dermatology at UT Southwestern, director of the connective tissue diseases clinic, and an expert in the treatment of cutaneous lupus. Participants will receive newsletters detailing the progress of the registry annually. Registration of study participants, which will require an in-person evaluation and consent, is already underway. For more information, please go to
Dermatomyositis:
Dermatomyositis Patient Registry at Stanford University Medical Center in Palo Alto, CA
We are interested in enrolling patients with dermatomyositis in order to better understand the disease and help find more effective and personalized therapies. Participants are asked to donate a blood sample as well as skin biopsy. If interested, please contact one of the two participating sites:
Stanford Department of Dermatology
Principal Investigator: David Fiorentino, MD, PhD
Contact: Amanda Foster
650-421-6103
Amfoster@stanford.edu
Dermatomyositis Patient Registry at University of Pennsylvania Medical Center in Philadelphia, PA
This is a study of dermatomyositis subjects who are followed during regularly scheduled clinic visits and are asked to provide data leading to evaluation of clinical responsiveness of their skin disease. Participants can donate a blood sample as well as skin biopsy. Studies relate to effectiveness of current treatments, studies to better understand the causes of the disease, and ways to improve treatments. If interested, please contact one of the two participating sites:
University of Pennsylvania
Principal Investigator: Victoria Werth, M.D.
Contact: Joyce Okawa
Phone: 215-898-0168
http://www.uphs.upenn.edu/dermatology/research-clinical-trials/clinical-trials.html